OU's Trading Corner (OTC)/ Now CDN Stocks and US Blue Chips (sorta)

[sublime]

APNS news...Emerging Stock Report: Emerging Stock Report: APNS Closes On First Test for Predicting Alzheimer's
Feb 24, 2005 (M2 PRESSWIRE via COMTEX) --
The Emerging Stock Report begins coverage today on Applied NeuroSolutions (OTCBB:APNS) a development stage biopharmaceutical company. In partnership with a team of scientists from Albert Einstein College of Medicine, the Company is developing an integrated product portfolio for the diagnosis and treatment of Alzheimer's disease. One of its wholly-owned operating subsidiary is Hemoxymed Europe, SAS, a development stage biopharmaceutical company that develops therapies aimed at improving tissue oxygenation by increasing oxygen release from hemoglobin to provide therapeutic value to patients with serious, medical needs.

The progress of APNS in this field of detection of Alzheimer`s was evidenced by coverage of their progress in Johns Hopkins Memory Bulletin. The Memory Bulletin is a quarterly publication of the prestigious John Hopkins University that gathers the most current information on preserving memory and coping with Alzheimer's disease and other forms of memory loss at every stage. The Memory Bulletin has commented on advances being made by APNS in the field of Alzheimer's disease diagnosis in an article entitled "A Spinal Fluid Test For Predicting AD" in its current issue.

Applied NeuroSolutions, in cooperation with major universities in the Unites States and APNS also announced in December 2004 it signed a non-exclusive agreement with bioMerieux, S.A with the aim of bringing to market on a worldwide basis what is expected to be the first definitive biologic test for the diagnosis of AD.

Alzheimer's disease (AD) is the most common form of dementia (a brain disorder that seriously affects a person's ability to carry out daily activities) among older people. It involves the parts of the brain that control thought, memory, and language. Every day scientists learn more, but right now the causes of AD are still unknown, and there is no cure.

Scientists think that up to 4 million Americans suffer from AD. The disease usually begins after age 60, and risk goes up with age. While younger people also may get AD, it is much less common. About 3 percent of men and women ages 65 to 74 have AD, and nearly half of those age 85 and older may have the disease.

As the baby boom generation ages the number of people afflicted by the diseases will rise dramatically. Companies who can aid in the detection, prevention or cure for the disease will bring help to millions and corresponding benefits to their shareholders. The Emerging Stock Report will continue to follow this emerging company and the sector and report back to astute investors

The Emerging Stock Report begins on: Med Gen, Inc. (OTCBB:MDGN), manufacturers of the national brands Snorenz(R), snore relief throat spray, and Good Nights Sleep(R), sleep aid throat spray.

SNORenz[R] is a throat spray which, according to the Company, reduces or eliminates the sounds ordinarily associated with snoring. The company's newest brand has been approved for sale at the nation's largest retailer.

Initially the brand will go on sale at 652 stores in April 2005 and then, based on performance, to be placed on the shelves of over 4,000 stores. The Company has had a similar experience with its Snorenz(R) Brand, which continues to sell well at these stores. The additional volume was expected to add $300,000 to present sales and eventually add over $1,000,000. Additionally, Cardinal Distribution has also agreed to handle distribution of Good Night's Sleep(R) to smaller chains and independent Drug stores. Med Gen also markets private label products and its own SnoreAway(R) brand into eight (8) foreign markets with a total population of 221.5 million people.

The sleep-aid category accounts for an estimated $1.6 billion in U.S. sales.

Presently, Good Night's Sleep(R) is the only sleep-aid available in a liquid throat-spray format, bringing faster action than traditional pills to those who suffer from sleep problems.. Catering to a market that is 10 times larger than the snoring category, Med Gen expects Good Night's Sleep(R) to double or triple its present sales.

Volume Alert Safe Travel Care Inc. (OTCBB:SFTV) is a travel protection insurance service company with administrative authority concerning product development, sales, marketing, distribution, premium collection, customer and distributor services, claims adjudication and payment, regarding the sale of its "Secure" and "Secure Plus" travel protection insurance plans.

Both plans focus on worldwide emergency medical evacuation and 24-hour emergency assistance with such essentials as: trip cancellation reimbursement, travel delay, baggage delay, lost baggage compensation, medical/dental expense coverage, flight insurance, and accidental death benefits all for a nominal cost per travel day.

The Company will launch its Secure and Secure Plus programs through a comprehensive advertising and marketing campaign via television, radio, Internet, print and business promotions. The campaign is designed to expose the availability and affordability of travel protection insurance to the American public.

Brent Gushowaty: Emerging Stock Report www.emergingstockreport.com

To receive a complimentary subscription to our Online Financial Newsletter please visit www.emergingstockreport.com .

All material herein was prepared by the EmergingStockReport.com, (ESR) based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.

ESR's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares' rise in value. Market commentary provided by Jason Ashdown ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements.

CONTACT: Jason Ashdown Tel: [phone] Brent Gushowaty e-mail: [e-mail] WWW: http://www.emergingstockreport.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail] .


--------------------------------------------------------------------------------

(C)1994-2005 M2 COMMUNICATIONS LTD

News provided by